Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
May Tun SaungStephen MuthDing DingDwayne L ThomasAlex B BlairTakahiro TsujikawaLisa CoussensElizabeth M JaffeeLei ZhengPublished in: Journal for immunotherapy of cancer (2018)
The conversion of exhausted PD-1+ T-cells to CD137+ activated effector T-cells may contribute to the anti-tumor effects of the anti-CSF-1R/anti-PD-1/GVAX combination therapy. Anti-CSF-1R antibody with anti-PD-1 antibody and GVAX have the potential be an effective therapeutic strategy for treatment of PDAC.